Munguva pfupi yapfuura, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yeChina yakazivisa kuti Encorafenib yakatenderwa kwenguva pfupi kuti iongororwe zvakanyanya. Ichashandiswa pamwe chete necetuximab uye FOLFOX chemotherapy regimen senzira yekutanga yekurapa varwere vakuru vane BRAF V600E-mutant metastatic colorectal cancer.
Izvi zvinoratidza kufambira mberi kukuru mukurapa kwegomarara iri rakaoma kurapa rinokonzerwa nekuchinja kwemajini.
**Chii chinonzi Encorafenib uye nei ichikosha?**
Encorafenib mushonga unodzivirira masero madiki eBRAF unosarudza zvakanyanya, une ATP-makwikwi. Muchidimbu, unonyanya kurwisa masero egomarara ane shanduko yeBRAF V600E, zvichidzivirira kukura kwawo nekuwanda kwawo. Kana tichienzanisa nemamwe ma BRAF inhibitors akambobvumidzwa, Encorafenib ine basa renguva refu remishonga, zvichireva kuti inoramba ichishanda mumuviri kwenguva yakareba.
**Ruzivo rweKiriniki: Humbowo hweKubudirira kweKushanda**
Musi wa25 Ndira, 2025, *Nature Medicine* yakaburitsa chidzidzo chekiriniki chePhase 3 cheEncorafenib + Cetuximab + chemotherapy yekurapa kenza yeBRAF-mutant colorectal. Chidzidzo cheBREAKWATER (NCT04607421) chaive nechinangwa chekuongorora kushanda kwe encorafenib pamwe necetuximab ine kana isina chemotherapy yakajairwa muvarwere vane kenza yeBRAF V600E-mutant colorectal. Huwandu hwevarwere 236 vakaiswa muboka rekuyedza uye 243 muboka rekuyedza. Mhedzisiro yakaratidza chiyero chemhinduro chakasimbiswa (cORR) che60.9% muboka rekuyedza, nevarwere vatatu vachiwana mhinduro yakazara (CR), 64 partial response (PR), uye 31 stable disease (SD). Muboka rekuyedza, cORR yaive 40.0%, ne2 CR, 42 PR, uye 34 SD. Nguva yepakati yekupindura (DOR) yaive 13.9 mwedzi ne11.1 mwedzi, zvichiteerana. Kurarama kwepakati kwemasero eropa kwaisagona kufungidzirwa muboka rekuyedza, zvichienzaniswa nemwedzi 14.6 muboka rekutonga.
**Kune Varwere Vepasi Pose: Dhipatimendi Repasi Pose reBeijing South Region Oncology Hospital Rinopa Rubatsiro Rwekurapwa Kwemhando Yepamusoro**
Iyi nzira yekurapa yepamusoro ikozvino yapinda munzira yekutanga yekuongorora muChina. Kune varwere vekune dzimwe nyika—kana iwe kana nhengo yemhuri yako iri kutsvaga nzira dziri nani dzekurapa—Beijing South Region Oncology Hospital International Department yakazvipira kushanda sebhiriji rehunyanzvi hwekurapa hwepamusoro hwepasi rose. Isu tinotevera zvakanyanya kuvandudzwa kwemishonga yepasi rose uye tinopa mazano ehunyanzvi uye rubatsiro rwekurapa kuvarwere vanokodzera.
**Tibatei Nhasi Kuti Mutange Rwendo Rwenyu rweTariro**
Usamirire. Mikana yese yekurapwa inogona kuchinja mararamiro. Chikwata chedu chekubatsira vanhu vanotaura mitauro yakasiyana-siyana chakagadzirira kupa mazano, kuronga nguva yekusangana, uye gwara rekurapa.
���Nhare yekubatsira vanhu kuti vasanyanya kutambura: 400-880-3716
���WeChat Instant Contact: ID: 17801183037
���Tsamba yemagetsi:
- Primary: `100085_010@163.com`
- Backup: `myimmnet@163.com`
Munogona kutibata kuburikidza nechero nzira dziri pamusoro apa. Varongi vedu vevarwere vepasi rose vachapindura nekukurumidza kuti vabatsire pakuronga zvinyorwa zvekurapa, kuongororwa kwesarudzo dzekurapa, uye chero mibvunzo nezvekutsvaga rubatsiro muBeijing. Dhipatimendi reBeijing South Region Oncology Hospital International rakagadzirira kutarisana nematambudziko nemi, nehunyanzvi uye netsitsi.
Nguva yekutumira: Kubvumbi-23-2026